Abstract
BACKGROUND: Evaluation of liver fibrosis appears to be easily overlooked in the clinic for the chronic Hepatitis D. Herein, we determine the Clinical Impact of liver fibrosis among HBsAg-positive/Anti-HDV positive US general adults. METHODS: Data were obtained from the National Health and Nutrition Examination Survey (NHANES) 1999-2020. Liver fibrosis was assessed by the Fibrosis-4 (FIB-4) and aspartate aminotransferase to platelet ratio index (APRI) score. To minimize confounding, propensity score matching (PSM) was applied to compare HBV/HDV-coinfected and HBV-monoinfected individuals. RESULTS: Out of 107,622 NHANES adults, 54,550 were tested for HBsAg and Anti-HDV, of whom 214 were identified as HBsAg-positive only, 50 were identified as HBsAg-positive/Anti-HDV-positive with available data for FIB-4/APRI. Mean APRI scores were 0.26 for the Non-Viral Hepatitis (NVH) group, 0.37 for the HBV group, and 0.42 for the HBV + HDV group. Corresponding mean FIB-4 scores were 1.07, 1.34, and 1.58, respectively. After PSM, HDV-infected individuals exhibited significantly higher fibrosis scores compared to HBV-positive individuals. CONCLUSION: Hepatitis D is more severe than hepatitis B, with a higher propensity to progress to liver fibrosis. These findings highlight the importance of routine fibrosis screening in HBsAg-positive/anti-HDV-positive individuals to prevent advanced liver disease.